Pericarditis

Summary

Pericarditis (MONDO:0005904) is a disease (an umbrella term covering 6 Mondo subtypes) with 19 GWAS associations across 13 studies and 38 clinical trials. Top therapeutic interventions include colchicine, anakinra, and rilonacept. A subtype of pericardium disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes
• GWAS associations: 19
• ClinVar variants: 1
• Clinical trials: 38

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pericarditis
Mondo ID	MONDO:0005904
EFO	EFO:0007427
MeSH	D010493
Orphanet	58208
DOID	DOID:1787
ICD-11	1296696944
NCIT	C34915
SNOMED CT	3238004
UMLS	C0031046
MedGen	18377
Is cancer (heuristic)	no

Also known as: inflammation of pericardium · pericarditis · pericarditis (disease) · pericardium inflammation

Data availability: 1 ClinVar variant · 19 GWAS associations (13 studies) · 1 HPO phenotype.

Disease family

This is a subtype of pericardium disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › pericardium disorder › pericarditis

Related subtypes (2): pericardial effusion, neoplasm of pericardium

Subtypes (6): Histoplasma pericarditis, Dressler syndrome, pericardial tuberculosis, constrictive pericarditis, viral pericarditis, rheumatic pericarditis

Genetics & variants

GWAS landscape

19 GWAS associations across 13 studies. Top hits map to 13 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs552767609	6e-13	GALNT16-AS1, EXD2	A	2.29
rs556330122	8e-13	HS3ST1 - LINC02360	G	2.32
rs567746402	9e-13	DNAJC8P3 - MIR4472-1	G	4.03
rs567653481	3e-12	COL25A1	T	2.79
rs564094809	3e-12	MIR3143 - RPL10P2	C	3.46
rs148428765	5e-12	MRPS21P6 - RPS27P18	C	3.04
rs568031359	7e-12	RN7SKP27 - LINC02923	C	3.05
rs181673904	9e-12	DPP4	C	3.94
rs190370190	1e-11	KCTD9P6 - RNA5SP261	A	2.4
rs187698017	2e-11	TRIP4	C	2.27
rs544749498	2e-11	RXRA	C	3.11
rs966455665	2e-11	LINC02450 - MRPS36P5	A	2.66
rs181429600	2e-11	GLDN	A	2.95
rs560709118	2e-11	RNA5SP443 - ARHGAP27	A	2.12
rs772660139	2e-11	SLC14A2-AS1, SLC14A2	G	2.77
rs568455465	2e-11	PEX10 - PLCH2	A	3.46
rs183394800	3e-11	ALDH1A2, LIPC-AS1, LIPC	G	2.74
rs144211882	4e-11	RN7SL366P - C6orf118	A	3.01
rs2895799	4e-11	PTPRQ	C	0.2

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90477893	Verma A	2024	3,729	442,899	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90018896	Sakaue S	2021	1,795	453,370	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90436091	Zhou W	2018	1,273	405,779	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90477892	Verma A	2024	1,246	119,287	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480145	Verma A	2024	1,246	119,287	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477894	Verma A	2024	769	449,707	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473554	UK Biobank Whole-Genome Sequencing Consortium	2025	673	457,767	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90481983	Verma A	2024	367	59,063	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480144	Verma A	2024	276	121,333	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481984	Verma A	2024	276	121,333	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	2
Tier 4: intronic/intergenic	17

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	18
unknown	0

Functional consequences

Consequence	Count
intron_variant	13
intergenic_variant	3
regulatory_region_variant	2
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs552767609	14	69203273	A>C	0.002	intron_variant	GALNT16-AS1, EXD2	6e-13	Tier 4: intronic/intergenic
rs556330122	4	11557934	G>A	0.001	intergenic_variant	HS3ST1 - LINC02360	8e-13	Tier 4: intronic/intergenic
rs567746402	8	142108045	G>A	0	non_coding_transcript_exon_variant	DNAJC8P3 - MIR4472-1	9e-13	Tier 4: intronic/intergenic
rs567653481	4	108935005	T>C,G	0.001	intron_variant	COL25A1	3e-12	Tier 4: intronic/intergenic
rs564094809	6	27187745	C>A,G,T	0	regulatory_region_variant	MIR3143 - RPL10P2	3e-12	Tier 3: regulatory
rs148428765	10	125217698	C>T	0.001	intron_variant	MRPS21P6 - RPS27P18	5e-12	Tier 4: intronic/intergenic
rs568031359	2	23281900	C>T	0	intergenic_variant	RN7SKP27 - LINC02923	7e-12	Tier 4: intronic/intergenic
rs181673904	2	162002899	C>T	0	intron_variant	DPP4	9e-12	Tier 4: intronic/intergenic
rs190370190	8	31541341	A>T	0.001	intron_variant	KCTD9P6 - RNA5SP261	1e-11	Tier 4: intronic/intergenic
rs187698017	15	64390763	C>A,T	0.003	intron_variant	TRIP4	2e-11	Tier 4: intronic/intergenic
rs544749498	9	134347727	C>T	0	intron_variant	RXRA	2e-11	Tier 4: intronic/intergenic
rs966455665	12	42830929	A>G	0.001	intron_variant	LINC02450 - MRPS36P5	2e-11	Tier 4: intronic/intergenic
rs181429600	15	51404072	A>G	0.001	intron_variant	GLDN	2e-11	Tier 4: intronic/intergenic
rs560709118	17	45370462	A>G	0.001	intron_variant	RNA5SP443 - ARHGAP27	2e-11	Tier 4: intronic/intergenic
rs772660139	18	45432882	G>C,T	0	intron_variant	SLC14A2-AS1, SLC14A2	2e-11	Tier 4: intronic/intergenic
rs568455465	1	2417593	A>G	0.001	intergenic_variant	PEX10 - PLCH2	2e-11	Tier 4: intronic/intergenic
rs183394800	15	58460656	G>C,T	0	intron_variant	ALDH1A2, LIPC-AS1, LIPC	3e-11	Tier 4: intronic/intergenic
rs144211882	6	165178309	A>T	0	regulatory_region_variant	RN7SL366P - C6orf118	4e-11	Tier 3: regulatory
rs2895799	12	80497071	C>A	0.135	intron_variant	PTPRQ	4e-11	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
3068593	NM_000257.4(MYH7):c.5119A>G (p.Ile1707Val)	LOC126861897	Uncertain significance	criteria provided, single submitter

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Rilonacept	Approved (phase 4)
Anakinra	Phase 3 (in late-stage trials)
Colchicine	Phase 3 (in late-stage trials)
Goflikicept	Phase 3 (in late-stage trials)
Hydroxychloroquine	Phase 3 (in late-stage trials)
Prednisolone	Phase 3 (in late-stage trials)
Prednisone	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cannabidiol.

Clinical trials & evidence

Clinical trials

Clinical trials: 38.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	18
PHASE2	7
PHASE3	6
PHASE4	3
PHASE2/PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00235079	PHASE4	COMPLETED	Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.
NCT00946907	PHASE4	TERMINATED	Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin
NCT04323280	PHASE4	TERMINATED	Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis
NCT05805930	PHASE3	NOT_YET_RECRUITING	Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
NCT06708299	PHASE3	RECRUITING	CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT07010159	PHASE2/PHASE3	RECRUITING	Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
NCT07245849	PHASE3	NOT_YET_RECRUITING	Pericardial Imaging Study
NCT00128414	PHASE3	COMPLETED	Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)
NCT00128453	PHASE3	COMPLETED	Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences
NCT03737110	PHASE3	COMPLETED	Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
NCT04692766	PHASE2/PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
NCT05107934	PHASE2/PHASE3	SUSPENDED	Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
NCT06836232	PHASE2	RECRUITING	An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT07288216	PHASE2	RECRUITING	Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT03224585	PHASE2	TERMINATED	Treatment of Acute Pericarditis With Anakinra
NCT03980522	PHASE2	COMPLETED	A Pilot Study of KPL-914 in Recurrent Pericarditis
NCT04906720	PHASE2	COMPLETED	Post-Ablation Pericarditis Reduction Study
NCT05494788	PHASE2	COMPLETED	Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
NCT06731595	PHASE2	COMPLETED	Post-Ablation Pericarditis Reduction Study (PAPERS)
NCT02083510	EARLY_PHASE1	COMPLETED	Apolipoprotein CIII Reduction Via Colchicine
NCT04687358	Not specified	ACTIVE_NOT_RECRUITING	REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
NCT04774549	Not specified	ACTIVE_NOT_RECRUITING	Inflammatory Cardiomyopathy Bern Registry
NCT05046002	Not specified	RECRUITING	COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry
NCT05925790	Not specified	RECRUITING	Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels
NCT06293924	Not specified	ENROLLING_BY_INVITATION	Pericardial Fluid Analysis in Recurrent Pericarditis
NCT06411340	Not specified	NOT_YET_RECRUITING	Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry (CAIR)
NCT06517966	Not specified	ACTIVE_NOT_RECRUITING	RUDRA Registry (Real-World Clinical Registry for Patients With Recurrent Pericarditis)
NCT06763549	Not specified	ENROLLING_BY_INVITATION	COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
NCT07077304	Not specified	NOT_YET_RECRUITING	EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
NCT07468461	Not specified	RECRUITING	CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome
NCT01063582	Not specified	UNKNOWN	Noise, a Risk for Heart in Airplane Pilots
NCT01395082	Not specified	COMPLETED	ACAM2000® Myopericarditis Registry
NCT02754713	Not specified	UNKNOWN	Prognostic Biomarkers in Patients With Acute Pericarditis
NCT03231449	Not specified	UNKNOWN	A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
NCT03253315	Not specified	UNKNOWN	Management of Pericarditis in Children.
NCT04294771	Not specified	UNKNOWN	JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
NCT06071156	Not specified	UNKNOWN	Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
NCT06103123	Not specified	UNKNOWN	MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
COLCHICINE	4	4
ANAKINRA	4	2
RILONACEPT	4	2
ASPIRIN	4	1
CANNABIDIOL	4	1
FLUDEOXYGLUCOSE F 18	4	1
GOFLIKICEPT	3	2
CHEMBL5220618	0	2
CHEMBL5282669	0	1